Saltar al contenido
Merck

Z-004

Zaleplon solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño


Acerca de este artículo

Fórmula empírica (notación de Hill):
C17H15N5O
Número CAS:
Peso molecular:
305.33
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-659-6
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Zaleplon solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

InChI key

HUNXMJYCHXQEGX-UHFFFAOYSA-N

InChI

1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3

SMILES string

CCN(C(C)=O)c1cccc(c1)-c2ccnc3c(cnn23)C#N

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

Gene Information

General description

Zaleplon is a nonbenzodiazepine “Z-drug” prescribed under the trade names Sonata® or Starnoc for the treatment of insomnia. Zaleplon is often abused illicitly for its mind-altering effects. This Certified Spiking Solution® is applicable to use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Sonata is a registered trademark of King Pharmaceuticals Research and Development, Inc.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Clase de almacenamiento

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Yu-Shu Huang et al.
Chang Gung medical journal, 34(1), 50-56 (2011-03-12)
Benzodiazepines cause a high proportion of adverse effects while non-benzodiazepine compounds have demonstrated high efficacy and less adverse effects in patients with insomnia. The objective of this study was to compare the effectiveness and safety of non-BZ zaleplon and zolpidem
Ane Birgitte Telén Andersen et al.
Pharmacoepidemiology and drug safety, 20(4), 378-385 (2011-01-25)
To estimate the degree of long-term use of zopiclone, zolpidem and zaleplon among Danes aged 65 and older and the association with sociodemographic factors and use of other drugs. Danish register-based study of 5000 men and 5000 women aged 65
Insomnia: evidence-based approaches to assessment and management.
Kevin Morgan et al.
Clinical medicine (London, England), 11(3), 278-281 (2011-09-10)
Karthik Y Janga et al.
Journal of microencapsulation, 30(2), 161-172 (2012-08-17)
Self-nanoemulsifying drug delivery systems (SNEDDSs) offer potential as suitable carriers for improved oral delivery of poorly soluble and low bioavailable drugs. To derive self-nanoemulsifying powders (SNEPs), the optimized Z-SNEDDS formulation was adsorbed onto different carriers and based on micromeritics the
A case of zaleplon-induced amnestic sleep-related eating disorder.
Shanna M Molina et al.
The Journal of clinical psychiatry, 71(2), 210-211 (2010-03-03)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico